Currently, only one PARP inhibitor, Olaparib (Lymparza, AstraZeneca, Esbo, Finland), has been approved by the FDA for cancer treatment and many challenges remained in the development or clinical utility of PARP inhibitors. This evidence concerns the gene PARP1 and cancer.